Digitisation | January 10, 2026
Revvity and Lilly partner to accelerate AI drug discovery models
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
The funding will accelerate Sinopia’s data-driven drug discovery efforts
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Peapod Bio’s proprietary technologies can efficiently identify inhibitors and binding molecules for virtually any target
New AI capabilities will help scientists identify, optimize, and validate new molecules. Additional applications include manufacturing, medical imaging, and enterprise AI agents
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
In this role, Neeraj will be responsible for crafting strategy, driving profitable growth through organic and inorganic models, expanding client base
Subscribe To Our Newsletter & Stay Updated
